Mohammad Saleh Fadaei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mohammad Saleh Fadaei has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Vafa Baradaran Rahimi
Patient Safety Research Center, Clinical Research Institute Mashhad University of Medical Sciences Mashhad Iran
2 shared publications - Vahid Reza Askari
Patient Safety Research Center, Clinical Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran
2 shared publications - Amir Emad Kheirieh1 shared publication
- Anahita Sadat Beheshti
Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication - Ermia Abedi
Pharmacological Research Center of Medicinal Plants, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication - Hooman Hatami1 shared publication
Latest Publications
- Open Access
- 11 September 2025
- Published by Elsevier in International Journal of Pharmaceutics: X
- Vol. 10
Overview of dendrimers as promising drug delivery systems with insight into anticancer and anti-microbial applications
- 11 September 2025
- Published by Elsevier in International Journal of Pharmaceutics: X
- Vol. 10
Open AccessOverview of dendrimers as promising drug delivery systems with insight into anticancer and anti-microbial applications
- 26 November 2024
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (4) , 3513-3526
Molecular, cellular, and metabolic insights of cinnamon (Cinnamomum zeylanicum) advantages in diabetes and related complications: condiment or medication?
Diabetes mellitus (DM) is a growing concern in public health, which affects about 10% of the population. There are several chronic complications due to DM, including kidney failure, blindness, amputations, myocardial infarction, and stroke. Cinnamon zeylanicum (C. verum, Ceylon cinnamon, or true cinnamon) has been shown to have desirable effects such as anti-obesity, anti-diabetic, anti-dyslipidemia, and anti-inflammatory effects in experimental studies. In this regard, Scopus, PubMed, and Google Scholar databases have been investigated with keywords of “Cinnamon,” “Cinnamomum zeylanicum,” “diabetes mellitus,” “diabetes complication,” “hypoglycemic,” “anti-hyperglycemic,” and “anti-diabetic” from incept to June 2024. This study aimed to review all pharmacological effects and molecular pathways of C. zeylanicum in DM and its complications in vitro, in vivo, and in clinical. Based on these studies, C. zeylanicum has good potential to design human studies for controlling and modifying DM and its related disorders.
- 26 November 2024
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (4) , 3513-3526
Molecular, cellular, and metabolic insights of cinnamon (Cinnamomum zeylanicum) advantages in diabetes and related complications: condiment or medication?
Diabetes mellitus (DM) is a growing concern in public health, which affects about 10% of the population. There are several chronic complications due to DM, including kidney failure, blindness, amputations, myocardial infarction, and stroke. Cinnamon zeylanicum (C. verum, Ceylon cinnamon, or true cinnamon) has been shown to have desirable effects such as anti-obesity, anti-diabetic, anti-dyslipidemia, and anti-inflammatory effects in experimental studies. In this regard, Scopus, PubMed, and Google Scholar databases have been investigated with keywords of “Cinnamon,” “Cinnamomum zeylanicum,” “diabetes mellitus,” “diabetes complication,” “hypoglycemic,” “anti-hyperglycemic,” and “anti-diabetic” from incept to June 2024. This study aimed to review all pharmacological effects and molecular pathways of C. zeylanicum in DM and its complications in vitro, in vivo, and in clinical. Based on these studies, C. zeylanicum has good potential to design human studies for controlling and modifying DM and its related disorders.